Finn Søndergaard – CEO, Intsel Chimos, France
Finn Søndergaard, CEO of Intsel Chimos, shares the motivation behind the company’s two recent acquisitions of Diverchim and Centre Lab, and the new strategic opportunities to expand as a full-service…
Intsel Chimos is an independent French laboratory with a long history of expertise in the import of medicines for patients in a therapeutic impasse and a partner of choice for hospitals. In 2010 and 2011, Intsel Chimos obtained orphan drug status from the EMA and the FDA respectively for a molecule intended for the treatment of gliomas (brain tumours), which marks the beginning of their transformation into a promising biotech player in France.
Contact
162 Bureaux de la Colline • 92213 SAINT CLOUD CEDEX • France
Tel: 01 49 11 66 80
Web: intselchimos.com
Email: contact@intselchimos.com
Finn Søndergaard, CEO of Intsel Chimos, shares the motivation behind the company’s two recent acquisitions of Diverchim and Centre Lab, and the new strategic opportunities to expand as a full-service…
Mr. Finn Søndergaard, CEO of Intsel Chimos, an independent French laboratory with a long history of expertise in the import of medicines for patients in a therapeutic impasse, highlights Intsel…
The Vice President of Health and Medicine at Pierre and Marie Curie University (UPMC) and Director of the University’s Institute of Oncology reveals how the French social security system needs…
The Director of the CNCR and the person in charge of the industrial sector, talk about the fragmented nature of French clinical research funding, why when it comes to boosting…
The President of France’s Association for CROs (AFCROs) discusses the issues surrounding France’s clinical research sector and the actions that both the public and private sector need to take to…
The president of Gedeon Richter France and CEO of PregLem, a Swiss-based biotech company acquired by Gedeon Richter in 2010, discusses the exciting synergies that have emerged from this partnership…
Pierre Banzet, President of Group Synerlab, one of the top ten French CMOs, discusses his group’s ambitious European expansion strategy, driven by their specialties in multi-dose, preservative-free eye drops, generics,…
The Director of the newly formed Necker Institute for Sick Children reveals how the inspiration behind INEM was to bring people together in order to create a common scientific policy…
Pfizer Global Established Products’ BU Head and Hospira’s Director of Institutional Affairs tell us about Pfizer’s recent major acquisition of Hospira, their post-merger strategy for increasing market access, as well…
The Head of the Department of Medical Oncology at the Pitié-Salpêtrière Hospital reveals how France is the only country in the world with universal and unlimited access to healthcare, how…
(© Sébastien Borda) The CEO of Novartis France reveals how the construction of a new French headquarters demonstrates a commitment to develop operations in the country, how the Huningue Biotechnology…
The general manager of Astellas France and president of LEEM, the French Pharmaceutical Companies Association, reveals how the pharmaceutical industry worldwide has to take into account what is a fair…
The President of Fefis, and the recently elected President of Medicen Paris Region, a Paris-based business cluster, talks about the need to build the future of the French health economy, not…
The director of GEMME reveals how the French generics market is young in comparison to other European countries – where generics were on the market twenty years before they became…
See our Cookie Privacy Policy Here
